Lexicon Pharmaceuticals, Inc. Share Price
Equities
LXRX
US5288723027
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.875 USD | +0.81% |
|
+5.40% | +61.30% |
| Capitalization | 788M 668M 616M 580M 1.08B 73.46B 1.1B 7.22B 2.83B 35.27B 2.96B 2.89B 125B | P/E ratio 2026 * |
-10.1x | P/E ratio 2027 * | -9.3x |
|---|---|---|---|---|---|
| Enterprise value | 788M 668M 616M 580M 1.08B 73.46B 1.1B 7.22B 2.83B 35.27B 2.96B 2.89B 125B | EV / Sales 2026 * |
23.2x | EV / Sales 2027 * | 40.1x |
| Free-Float |
98.44% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Lexicon Pharmaceuticals, Inc.
| 1 day | +0.81% | ||
| 1 week | +5.40% | ||
| Current month | +18.91% | ||
| 1 month | +15.22% | ||
| 3 months | +35.40% | ||
| 6 months | +26.19% | ||
| Current year | +61.30% |
| 1 week | 1.69 |  | 1.87 |
| 1 month | 1.49 | | 1.87 |
| Current year | 1.1 | | 1.87 |
| 1 year | 0.49 | | 1.87 |
| 3 years | 0.28 | | 3.79 |
| 5 years | 0.28 | | 6.33 |
| 10 years | 0.28 | | 19.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Exton
CEO | Chief Executive Officer | 56 | 07/07/2024 |
Scott Coiante
DFI | Director of Finance/CFO | 59 | 01/01/2025 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Samuel Barker
CHM | Chairman | 83 | 31/12/2004 |
Ray Debbane
CHM | Chairman | 71 | 26/02/2012 |
| Director/Board Member | 67 | 27/08/2007 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.02% | 0% | 7 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.81% | +5.40% | +271.00% | -31.04% | 788M | |
| -0.56% | +4.35% | +34.89% | +100.34% | 52.12B | |
| +0.26% | +2.98% | +103.18% | +24.51% | 47.25B | |
| -2.58% | -10.31% | +103.89% | +700.06% | 31.67B | |
| -0.15% | +8.17% | +1.27% | -20.24% | 25.15B | |
| +0.49% | +4.61% | +84.06% | -31.28% | 19.54B | |
| -2.09% | +0.50% | +40.26% | -37.64% | 17.83B | |
| +1.09% | +9.96% | +78.02% | +240.57% | 17.33B | |
| +8.64% | +19.28% | -0.07% | +1,339.62% | 16.38B | |
| +0.58% | +7.58% | +80.62% | - | 15.45B | |
| Average | +0.59% | +5.15% | +79.71% | +253.88% | 24.35B | |
| Weighted average by Cap. | +0.13% | +3.53% | +62.36% | +231.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.92M 28.74M 26.5M 24.99M 46.6M 3.16B 47.35M 311M 122M 1.52B 127M 125M 5.39B | 19.63M 16.63M 15.34M 14.46M 26.97M 1.83B 27.41M 180M 70.4M 879M 73.66M 72.12M 3.12B |
| Net income | -72.4M -61.33M -56.55M -53.33M -99.46M -6.75B -101M -663M -260M -3.24B -272M -266M -11.5B | -91.47M -77.48M -71.45M -67.37M -126M -8.53B -128M -838M -328M -4.09B -343M -336M -14.53B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/04/26 | 1.865 $ | +0.27% | 369,089 |
| 15/04/26 | 1.860 $ | +6.29% | 2,135,662 |
| 14/04/26 | 1.750 $ | +2.34% | 1,257,529 |
| 13/04/26 | 1.710 $ | -0.58% | 838,359 |
| 10/04/26 | 1.720 $ | -2.27% | 1,368,261 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LXRX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition